合并动脉高血压与主动脉瓣狭窄患者的管理:欧洲心脏病学会高血压委员会与瓣膜性心脏病委员会、欧洲心血管影像协会(EACVI)及欧洲经皮心血管介入协会(EAPCI)的共识文件
该共识指出主动脉瓣狭窄(AS)与动脉高血压常随年龄增长而共存,共存时左心室整体压力负荷更高、左室几何形态与功能更异常、心血管结局更差,高血压还可能影响AS分级而低估真实严重程度。现有指南建议高血压控制后重新评估AS严重程度;当前证据提示应使用阻断肾素-血管紧张素-醛固酮系统的降压药,必要时联合其他药物,使血压达标水平与不合并AS的高血压患者相似。经导管主动脉瓣植入术改变了AS管理格局,但瓣膜置换术中及术后需做好血压管理。
要点
- 高血压可影响AS分级,导致低估真实AS严重程度,指南建议血压控制后重新评估
- AS合并高血压提示左室整体压力负荷更高、左室几何形态与功能更异常、心血管结局更差
- 使用阻断肾素-血管紧张素-醛固酮系统药物,必要时联合其他药物,使血压达标水平与不合并AS者相似
核心结论
- AS与动脉高血压常共存,共存与更高的左室整体压力负荷、更异常的左室几何形态与功能及更差的心血管结局相关。
- 动脉高血压可能影响AS分级,导致低估真实AS严重程度;当前指南建议高血压控制后重新评估患者。
- 当前证据提示应使用阻断肾素-血管紧张素-醛固酮系统的降压药,必要时联合其他药物,使血压达标水平与不合并AS的高血压患者相似。
- 经导管主动脉瓣植入术彻底改变了AS患者的管理,但瓣膜置换术中及术后需要恰当的血压管理。
研究设计与样本
- 本文为欧洲心脏病学会高血压委员会与瓣膜性心脏病委员会、欧洲心血管影像协会(EACVI)及欧洲经皮心血管介入协会(EAPCI)联合发布的共识文件。
- 文件目的是回顾近期证据,并就AS合并高血压的管理提供实用性专家建议。
诊断标准与关键数值
- 当前指南建议在动脉高血压得到控制后对患者重新评估。
- 当前证据提示使用阻断肾素-血管紧张素-醛固酮系统的降压药,必要时加用其他药物类别,使血压达标水平与不合并AS的高血压患者相似。
临床应用与阅片要点
- 对AS患者评估严重程度时需考虑合并动脉高血压对分级的影响,高血压控制后重新评估。
- AS合并高血压的降压治疗历史上因担心药物性外周血管扩张与固定左室流出道梗阻所致每搏输出量降低的不良后果而趋于谨慎。
- 经导管主动脉瓣植入术围术期及术后需进行恰当的血压管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Aortic valve stenosis (AS) is the third most common cardiovascular disease. The prevalence of both AS and arterial hypertension increases with age, and the conditions therefore often co-exist. Co-existence of AS and arterial hypertension is associated with higher global left ventricular (LV) pressure overload, more abnormal LV geometry and function, and more adverse cardiovascular outcome. Arterial hypertension may also influence grading of AS, leading to underestimation of the true AS severity. Current guidelines suggest re-assessing patients once arterial hypertension is controlled. Management of arterial hypertension in AS has historically been associated with prudence and concerns, mainly related to potential adverse consequences of drug-induced peripheral vasodilatation combined with reduced stroke volume due to the fixed LV outflow obstruction. Current evidence suggests that patients should be treated with antihypertensive drugs blocking the renin-angiotensin-aldosterone system, adding further drug classes when required, to achieve similar target blood pressure (BP) values as in hypertensive patients without AS. The introduction of transcatheter aortic valve implantation has revolutionized the management of patients with AS, but requires proper BP management during and following valve replacement. The purpose of this document is to review the recent evidence and provide practical expert advice on management of hypertension in patients with AS.
引用
- Mancusi C, de Simone G, Brguljan Hitij J, et al. Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32353143. doi:10.1093/ehjcvp/pvaa040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。